The Cholesterol Conversation Women Are Not Having Until It Is Late
Cardiovascular disease causes roughly one in three deaths among women each year — more than all forms of cancer combined. And yet the share of women who recognize it as their leading health risk has been falling for over a decade. For women in their forties and fifties, the menopause transition is a distinct window of accelerating risk. Here's what the standard lipid panel doesn't tell you, and what's worth asking about.
Last updated: September 2026
Most women I meet who are worried about their cholesterol have a similar story. A lab result appeared in their patient portal, one number was flagged in red or yellow, and the attached message said something like, "borderline, we will recheck next year." Without context, an explanation of what changed, or a plan, it’s no wonder many women worry. September is National Cholesterol Education Month, and World Heart Day falls on September 29, so this is a reasonable time to take a closer look at your heart health. For women in their forties and fifties, a cholesterol number is not a standalone fact, but a snapshot taken during a period when the underlying biology is actively shifting.
This post covers why cardiovascular risk changes during the menopause transition, what a standard lipid panel does and does not tell you, and which additional markers are worth asking about. It’s also worth noting that I am writing this as a Menopause Society Certified Practitioner and as a physician who focuses on preventive medicine. This means that the hormonal side of this shift is something I evaluate directly rather than treat as coincidence.
The Framing Problem
Cardiovascular disease is the leading cause of death in women. The American Heart Association's Go Red for Women initiative reports that it causes roughly one in three deaths among women each year, which is more than all forms of cancer combined.
Awareness has moved in the wrong direction. A special report published in Circulation found that the share of women who identified cardiovascular disease as the leading cause of death in women fell from 65% in 2009 to 44% in 2019, with the decline showing up across nearly every age and racial group except women 65 and older. The group of women least likely to recognize the risk was the youngest, even though they have the most time to act on it.
That gap has a practical consequence in the exam room. When a 47-year-old woman brings me a list of concerns, heart risk is almost never on it, but sleep, weight, brain fog, joint aches, and mood usually are. All these common symptoms of menopause are worth taking seriously on their own terms, but taking the chance to look at her lipids is also just as important.
What Actually Changes During the Menopause Transition
In 2020, the American Heart Association issued a scientific statement specifically on the menopause transition and cardiovascular risk. Its central argument is that the transition is a distinct window of accelerating risk, not simply a birthday you pass through. Among the changes it describes:
Lipids shift. LDL cholesterol and apolipoprotein B (ApoB) rise during the transition, and the statement attributes this more directly to the hormonal change than to chronological aging alone.
Body composition changes independently of the scale. Visceral fat increases and lean muscle mass decreases, increasing cardiovascular risk even in women whose overall weight hasn't changed. This is the single most common source of frustration I hear: “the scale looks the same, but my body does not.” What may not be visible to the naked eye is the change in labs.
The window matters. The statement frames the transition as a time to intensify risk assessment rather than wait. The reasoning is that changes accumulating in a woman’s forties and fifties show up in her sixties and seventies.
Activity levels are usually not where they need to be. The statement notes that only about 7% of perimenopausal women meet recommended physical activity levels, which is a striking figure given how much of risk modification depends on it.
None of this means the transition causes heart disease, and none of it means a rising LDL requires medication. What it does mean is that your lab interpretation should account for where you are in the transition, and unfortunately, most fifteen-minute visits don't leave room for that conversation. I have written separately about what your doctor should be discussing with you about perimenopause and menopause and about why midlife women need a more connected approach to care.
What a Standard Lipid Panel Measures
A conventional lipid panel gives four values, and it helps to know what each one is actually doing.
Total cholesterol. This is a sum, not a diagnosis. For context, CDC data from 2017 to 2020 found that about 10% of adults age 20 and older had total cholesterol above 240 mg/dL, and roughly 86 million adults were above 200 mg/dL.
LDL cholesterol. This is the value most often flagged, and in most standard panels, it is calculated rather than measured directly.
HDL cholesterol. This has long been treated as straightforwardly protective, though the research on that has become more nuanced, particularly in women across the menopause transition.
Triglycerides. Triglycerides are sensitive to recent food, alcohol, and metabolic changes, which is part of why fasting status matters for interpretation.
These four values are genuinely useful, but for a woman in her forties or fifties, these do not capture the full story.
What the Panel Does Not Tell You
A lipid panel cannot answer several questions that materially change what you should do next:
How many atherogenic particles you are actually carrying, as opposed to how much cholesterol they contain
Whether you have an inherited lipoprotein risk that will not move with diet and exercise
Whether plaque is already present in your coronary arteries
Whether your reproductive history carries risk information that the standard risk calculator does not capture
Where you are in the menopause transition, and therefore whether this year's number represents a trend or a fluctuation
That last one is not a lab limitation but a visit-length limitation. Nobody can build a risk picture from a portal message!
The Markers Worth Asking About
The 2018 AHA/ACC multisociety cholesterol guideline formalized the idea that the standard risk calculator is a starting point, and it named a set of "risk-enhancing factors" that should push the conversation further. Two of them are specific to women: a history of preeclampsia and premature menopause. If you had a hypertensive pregnancy twenty years ago, that belongs in this conversation, and it is very often absent from it.
The guideline also points toward three tests worth knowing by name:
Lipoprotein(a), or Lp(a). This is largely genetically determined and typically measured once in a lifetime. The guideline treats a level above 50 mg/dL as a risk enhancer, but many women with a family history of early heart disease and unremarkable standard labs have never had it checked.
Apolipoprotein B (ApoB). This is a direct count of atherogenic particles. The guideline treats a level above 130 mg/dL as a risk enhancer, and it is one of the markers the AHA menopause statement identifies as rising during the transition.
Coronary artery calcium (CAC) scoring. This is a low-dose CT that looks for calcified plaque. The guideline positions it as a tie-breaker for people at borderline or intermediate calculated risk who are uncertain about starting therapy. A score of zero and a score in the hundreds point toward genuinely different conversations.
I am describing these as questions to raise with your physician, not as tests everyone needs. Whether any of them is appropriate depends on your history, your family history, and your calculated risk. Decisions about medication, including whether to start one at all, belong in a full clinical discussion and not in a blog post.
Why "Borderline" Is a Conversation, Not a Result
Here is what makes the portal-message version of this so unsatisfying. "Borderline" is precisely the category where the additional information changes the answer. A woman with borderline numbers, a clean family history, no reproductive risk factors, and a calcium score of zero is in a different position than a woman with identical labs, an elevated Lp(a), and a mother who had a heart attack at 58. The lipid panel is the same, but the plan should be completely different.
The treatment gap is real in both directions. CDC data indicate that about 54.5% of US adults who could benefit from cholesterol medication are taking it. This means a substantial number of people who would benefit are not on therapy, while others are started without the in-depth conversation that would have made the decision feel like theirs.
Sorting that out takes time. It takes reviewing your labs alongside your reproductive history, your family history, your blood pressure trend, your activity level, and where you are in the transition. From there, you and your physician should together decide what to do about it. That is the practical case for longer appointments and for preventive care that gets actual time on the schedule, which is how this practice is built.
What to Ask For at Your Next Cholesterol Check
Whether you are a patient here or anywhere else, these are the questions I would want a woman over 40 to bring to a cholesterol screening in Chapel Hill or anywhere:
What is my calculated ten-year cardiovascular risk, and what went into that number?
Do any of the risk-enhancing factors apply to me, including a history of preeclampsia, gestational diabetes, or early menopause?
Have I ever had a lipoprotein(a) measured, and given my family history, should I?
Is ApoB worth adding to my panel?
Am I at a risk level where a coronary calcium score would change the decision?
What would we do first if my numbers keep moving in the same direction?
What does my perimenopause status have to do with any of this?
You are not being difficult by asking these. You are asking your physician to interpret a number instead of just reporting it.
To discuss preventive screening in Chapel Hill, NC, or to learn how membership works at Concierge Medicine of Chapel Hill, visit our Membership and Services page or call 919-827-0009 to schedule a meet-and-greet with Dr. Repine.
